Oxidoreductases (1. ) (e.g., Catalase, Dehydrogenases, Reductases, Etc.) Patents (Class 424/94.4)
-
Publication number: 20110110913Abstract: A method of inducing NAD+ synthesis in a subject. The method comprises administering to the subject a therapeutically effective amount of resveratrol or a functionally equivalent analogue or derivative thereof. NAD+ synthesis increases the activity of Poly(ADP-ribose) polymerase (PARP) enzymes and sirtuin enzymes. The PARP enzyme is PARP-1 or PARP-2 and the sirtuin enzyme is selected from the group consisting of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7.Type: ApplicationFiled: March 3, 2009Publication date: May 12, 2011Inventors: Ross Stewart Grant, Nady Braidy, Gilles Guillemin, George Smythe
-
Publication number: 20110111006Abstract: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.Type: ApplicationFiled: January 14, 2011Publication date: May 12, 2011Applicant: RAMSCOR, INC.Inventors: Vernon G. WONG, Louis L. Wood
-
Publication number: 20110104103Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.Type: ApplicationFiled: July 20, 2006Publication date: May 5, 2011Applicant: KREATECH BIOTECHNOLOGY B.V.Inventors: Robert Jochem Heetebrij, Robbert Jan Kok, Eduard Gerhard Talman, Klaas Poelstra, Grietje Molema
-
Publication number: 20110104240Abstract: The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides methods and uses for treating wounds, microbial infections and dermatological disorders and for preserving meat products.Type: ApplicationFiled: June 23, 2009Publication date: May 5, 2011Applicant: Micropharma LimitedInventors: Mitchell Lawrence Jones, Satya Prakash
-
Publication number: 20110104059Abstract: To gain a better understanding of tumor angiogenesis endothelial cells (ECs) were isolated and gene expression patterns were evaluated. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed differentially expressed genes, including many that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level.Type: ApplicationFiled: May 6, 2009Publication date: May 5, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Brad ST. CROIX, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Publication number: 20110104225Abstract: A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.Type: ApplicationFiled: August 13, 2008Publication date: May 5, 2011Applicants: Ramot At Tel Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Shimon Rochkind, Zvi Nevo
-
Publication number: 20110106000Abstract: The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides compositions, methods and uses for skin cosmesis.Type: ApplicationFiled: June 23, 2009Publication date: May 5, 2011Applicant: MICROPHARMA LIMITEDInventors: Mitchell Lawrence Jones, Satya Prakash
-
Publication number: 20110104114Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidized polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.Type: ApplicationFiled: June 26, 2009Publication date: May 5, 2011Inventors: Gord Adamson, David Bell, Steven Brookes
-
Publication number: 20110097391Abstract: This present invention relates generally to the field of chemistry, food industry, cosmetics, and pharmaceutical industry. More specifically, the present invention relates to liposomal biologically active forms and methods of producing thereof. The present invention provides a stable phospholipid emulsion based on dihydroquercetin (DHQ), its compounds and derivatives. The invention further provides a method a quite simple and economic method for the preparation of disclosed emulsion. The disclosed emulsion is characterized by the improved bioavailabilty and selectivity of the effect of active compounds and by the increased stability and prolonged storage terms. The claimed result is achieved using a phospholipid emulsion containing DHQ, its compounds and/or derivatives, at least one membrane-forming phospholipid, at least one zwitter-ion amino acid base, aminoacetic ether, and aqueous ethanol in the following ratio of components (wt %): Dihydroquercetin, 0.01-3; Phospholipid, 0.Type: ApplicationFiled: December 30, 2010Publication date: April 28, 2011Applicant: Obschestvo S Ogranichennoi Otvetstvennostju Scientific Company FlamenaInventors: Aleksej Mikhajlovich Grigor'ev, Anton Vladimirovich Evteev, Andrej Petrovich Smyslov, Pjotr Andreevich Smyslov, Andrej Petrovich Smyslov, Maksim Vjacheslavovich Cvetkov
-
Publication number: 20110091438Abstract: The invention refers to a specific isoform of MnSOD (Mn-superoxide dismutase) and its uses for protecting and curing subjects exposed to radiations, specifically space radiations.Type: ApplicationFiled: October 20, 2009Publication date: April 21, 2011Applicant: ASI AGENZIA SPAZIALE ITALIANAInventor: Aldo Mancini
-
Publication number: 20110091414Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.Type: ApplicationFiled: October 12, 2010Publication date: April 21, 2011Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
-
Patent number: 7927852Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: GrantFiled: August 3, 2007Date of Patent: April 19, 2011Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 7927589Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: August 3, 2007Date of Patent: April 19, 2011Assignee: Mountain View Pharmaceuticals, Inc.Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Patent number: 7927621Abstract: A poly(thioester ester amide) copolymer and method of making and using the same are disclosed.Type: GrantFiled: June 25, 2007Date of Patent: April 19, 2011Assignee: Abbott Cardiovascular Systems Inc.Inventors: Mikael O. Trollsas, Nam D. Pham, Michael H. Ngo, Bozena Zofia Maslanka
-
Patent number: 7927588Abstract: A skin dressing comprises a first dressing component (16) carrying oxidoreductase enzyme in dried condition; and a second dressing component (18) carrying a source of water, such that when the first and second dressing components are placed in fluid communication with each other, water migrates from the second component towards the first comportent and acts to hydrate enzyme carried by the first component, at least at the surface of the first component. The dressing components are kept separate before use, e.g. being sealed in separate sterile, water-impervious packages such as laminated aluminum foil pouches. In use of the dressing, the second dressing component is located on the skin of a human or animal, e.g. over a wound to be treated or on a region of skin to be treated for cosmetic or therapeutic purposes such as for treatment of acne or other skin conditions. The first dressing component is placed on top of the second component in fluid communication therewith.Type: GrantFiled: June 4, 2004Date of Patent: April 19, 2011Assignee: Archimed LLPInventors: Paul James Davis, Andrew John Austin
-
Publication number: 20110081421Abstract: The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can be activated by the body as needed. Active renalase protein can be administered to individuals needing an immediate reduction of catecholamine levels. An inhibitor of renalase may be used to enhance adrenergic action.Type: ApplicationFiled: November 15, 2010Publication date: April 7, 2011Applicant: YALE UNIVERSITYInventors: GARY DESIR, JIANCHAO XU
-
Publication number: 20110081394Abstract: Provided is a method of attaching a molecule-of-interest to a microtube, by co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming a coat over an internal surface of the shell, the first polymeric solution is selected solidifying faster than the second polymeric solution and a solvent of the second polymeric solution is selected incapable of dissolving the first polymeric solution and wherein the second polymeric solution comprises the molecule-of-interest, thereby attaching the molecule-of-interest to the microtube. Also provided is an electrospun microtube comprising an electrospun shell, an electrospun coat over an internal surface of the shell and a molecule-of-interest attached to the microtube.Type: ApplicationFiled: February 12, 2009Publication date: April 7, 2011Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.Inventors: Eyal Zussman, Yael Dror, Jonathan Charles Kuhn
-
Publication number: 20110076233Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.Type: ApplicationFiled: December 9, 2010Publication date: March 31, 2011Applicant: IMMUNOMEDICS, INC.Inventors: William J. McBride, Christopher A. D'Souza, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20110070216Abstract: Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress.Type: ApplicationFiled: September 8, 2010Publication date: March 24, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventor: Carlo DANI
-
Publication number: 20110070217Abstract: The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurin, and/or Pseudomonas aeruginosa cytochrome c551 and their use in inhibiting of viral infection, and in particular infection of mammalian cells by the Human Immunodeficiency Virus (HIV). The invention also relates to variants and derivatives of cupredoxin and cytochrome c that retain the ability to inhibit viral infection, and in particular infection by the Human Immunodeficiency Virus (HIV). The invention also relates to research methods for studying viral and bacterial infection in mammalian cells.Type: ApplicationFiled: September 13, 2010Publication date: March 24, 2011Inventors: ANANDA CHAKRABARTY, TAPAS DAS GUPTA, TOHRU YAMADA, ANITA CHAUDHARI, ARSENIO FIALHO, CHANG SOO HONG
-
Publication number: 20110070198Abstract: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target.Type: ApplicationFiled: December 23, 2008Publication date: March 24, 2011Inventors: Alexander L. Huang, Gin Wu
-
Patent number: 7906109Abstract: The present invention relates to the pharmaceutical composition comprising a non-detergent sulphobetaine (NDSB).Type: GrantFiled: December 22, 2004Date of Patent: March 15, 2011Assignee: Lek Pharmaceuticals d.d.Inventors: Viktor Menart, Vladka Gaberc Porekar, Barbara Podobnik
-
Publication number: 20110052661Abstract: An edible product for oral hygiene of a pet, the product being chewable by the pet to remove plaque, tartar and stain from the teeth of the pet and to reduce breath odor of the pet. The dental hygiene product includes a body formed of a first set of constituent components and a second set of constituent components, the first set of constituent components including abrasive components and one or more breath freshening components, the combination when chewed by the pet effecting the removal of plaque, tartar and stain and the inhibition of breath odor, the second set of constituent components including an abrasive component and one or more active components, the abrasive component when chewed by the pet effecting the removal of plaque, tartar and stain from the teeth of the pet, the one or more active components being characterized by the active components disrupting growth of bacteria in the pet's mouth thereby inhibiting plaque and tartar formation and breath odor from a bacterial source.Type: ApplicationFiled: February 13, 2009Publication date: March 3, 2011Inventor: Susan Datz Weiss
-
Publication number: 20110052557Abstract: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target.Type: ApplicationFiled: August 25, 2010Publication date: March 3, 2011Inventors: ALEXANDER L. HUANG, Gin Wn
-
Publication number: 20110052678Abstract: A method for treating age related macular degeneration uses insulin preparation applied topically in a therapeutically effective amount to an affected conjunctival sac of the eye. The topically effective dose is delivered to the fovea centralis and macula lutea. In other embodiments, additional therapeutic, pharmaceutical, biochemical, nutriceutical, biological (monoclonal antibodies and others) agent or compound, and organic and inorganic agents are also applied to the afflicted site through the conjunctival sac and choroidal vascular system of the eye. IGF-1 may be applied as well with or without insulin to treat ARMD.Type: ApplicationFiled: November 5, 2010Publication date: March 3, 2011Inventors: Totada R. Shantha, Jessica Shantha, Erica Maya Shantha
-
Publication number: 20110044966Abstract: A method for treatment and/or prevention of common cold caused by rhinovirus, wherein a patient in need is treated with a medicament including a hydrogen peroxide producing enzyme.Type: ApplicationFiled: March 20, 2009Publication date: February 24, 2011Inventor: Krister Tano
-
Publication number: 20110033391Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having transferase activity, e.g., transaminase activity, e.g., d-amino-acid transferase activity, and/or oxidoreductase activity, e.g., dehydrogenase activity, e.g., damino-acid dehydrogenase activity, and/or catalyze the transfer of a chemical group, catalyze transamination, catalyze the reaction: D-alanine+2-oxoglutarate<=>pyruvate+D-glutamate, and/or catalyze an oxidation-reduction reaction, catalyze the removal of hydrogen atoms, and/or catalyze the reaction: D-amino acid+H2O+acceptor<=>a 2-oxo acid+NH3+reduced acceptor.Type: ApplicationFiled: December 31, 2008Publication date: February 10, 2011Applicant: VERENIUM CORPORATIONInventors: David P. Weiner, Peter Luginbuhl, Analia Bueno, Joslin M. Cuenca, Erin Marasco
-
Publication number: 20110033392Abstract: The present invention provides a deodorizing composition containing as an active ingredient thereof a natural plant extract with high safety, which can be used for foods without any anxiety concerning safety in use and shows a high deodorizing effect even in a weakly acidic condition, and foods and drinks containing such a composition. The deodorizing composition comprises a plant of the genus Rubus of the family Rosaceae, laccase and an acid.Type: ApplicationFiled: February 6, 2009Publication date: February 10, 2011Inventors: Atsushi Narise, Takahito Takase, Sanae Kikuchi, Kenji Osawa
-
Publication number: 20110033549Abstract: A dry composition for use in therapy or diagnosis, obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffer has a pKa that is at least 1 unit greater or less than the pH of the aqueous composition, and wherein the aqueous composition is substantially free of a conventional buffer having a pKa that is within one pH unit of the pH of the aqueous composition.Type: ApplicationFiled: August 5, 2010Publication date: February 10, 2011Inventors: Jan Jezek, Charles Potter
-
Publication number: 20110027251Abstract: Novel uses for 4-phenylbutyrate (4PBA) and its pharmaceutically acceptable salts The use of 4PBA in the manufacture of a medicament useful to treat cognitive disorders in dementias coursing with tauopathies is described. The treatment with 4PBA improves cognitive deficit in a classic murine experimental model of Alzheimer's Disease (AD) (Tg 2576) that is accompanied by decreasing levels of a marker characteristic to AD pathologies, such as phosphorylated Tau, and increasing levels in the synthesis of some synaptic plasticity marker proteins such as GluR1 and PSD95. As mediating mechanism for the therapeutic effect we propose a decreasing stress in the endoplasmic reticulum as manifested by increasing levels of the GRP78 protein. On the other hand its inhibiting effect on histone deacetylation and its involvement in chromatin remodeling facilitates protein synthesis processes, which improves synaptic plasticity.Type: ApplicationFiled: March 6, 2009Publication date: February 3, 2011Inventors: Diana Sara Frechilla Manso, Ana MarÃa GarcÃa Osta, Luis Alberto Pérez Media Villa, Ana Lourdes Ricobaraza Abarquero
-
Publication number: 20110027250Abstract: The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant. In one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane.Type: ApplicationFiled: July 29, 2010Publication date: February 3, 2011Applicant: Northwestern UniversityInventors: Phillip B. Messersmith, Carrie Brubaker, Andreas H. Zisch, Corinne Zisch
-
Publication number: 20110027183Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. Any kind of compound, but in particular drugs, such as interferons, viral reverse transcriptase inhibitors or core assembly inhibitors, and/or labels can be specifically targeted to the liver and so be enriched in the liver. This liver targeting can further be used for the targeted diagnosis, prevention and/or treatment of liver diseases or disorders, such as hepatitis, malaria, hepatocellular carcinoma (HCC), as well as for the prevention of HAV, HBV, HCV and/or HDV infection. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified preS-derived peptide(s) and the compound(s) to be specifically delivered to the liver.Type: ApplicationFiled: January 26, 2009Publication date: February 3, 2011Inventors: Walter Mier, Uwe Haberkorn, Stephan Urban
-
Publication number: 20110020301Abstract: The use of S-adcnosylmcthioninc (SAM) in combination with supcmxidc dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.Type: ApplicationFiled: February 25, 2009Publication date: January 27, 2011Applicant: GNOSIS S.P.A.Inventors: Sigfrido Scarpa, Andrea Fuso, Rosellina Damiani, Mauro Rossini
-
Publication number: 20110020432Abstract: The present disclosure is directed to methods of administering RL1P76 or an active fragment thereof more than 24 hours after radiation exposure, wherein administration is effective for the protection and treatment of mammals exposed to radiation. In addition, compositions are disclosed including RLIP76 and other radioprotective agents, for example antioxidants.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: TERAPIO CORPORATIONInventor: C. Casey Cunningham
-
Publication number: 20110014174Abstract: A method of reducing a vasodilatory response comprising administering to an individual in need of such treatment an effective amount of a guanylate cyclase pathway inhibitor selected from the group consisting of methylene blue, ODQ, LY83583 and a protein kinase G inhibitor or an H2O2 reducing agent selected from the group consisting of Aspergillus niger catalase and hydroxyl scavengers, hydroquinone and mannitol.Type: ApplicationFiled: August 28, 2008Publication date: January 20, 2011Applicant: UNIVERSITY OF MANITOBAInventors: Steven Mink, Krika Kasian, Hans Jacob, Robert Bruce Light
-
Publication number: 20110014277Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.Type: ApplicationFiled: September 29, 2010Publication date: January 20, 2011Inventor: Harlan Clayton Bieley
-
Publication number: 20110014176Abstract: This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.Type: ApplicationFiled: March 13, 2009Publication date: January 20, 2011Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Michael K. Bamat, Reid W. von Borstel, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20110014175Abstract: The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.Type: ApplicationFiled: June 28, 2010Publication date: January 20, 2011Applicant: BASF Beauty Care Solutions France S.A.S.Inventors: Eric Perrier, Valérie Cenizo, Charbel Bouez, Pascal Sommer, Odile Damour, Claudine Gleyzal, Valérie Andre, Corinne Reymermier
-
Publication number: 20110008310Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.Type: ApplicationFiled: May 2, 2008Publication date: January 13, 2011Applicant: The McLean Hospital CorporationInventors: Anne M. Cataldo, Peter A. Paskevich, Bruce M. Cohen
-
Publication number: 20110008402Abstract: The present invention provides compositions comprising an antibiofilm enzyme, a soluble ?-N-acetylglucosaminidase similar to the dspB gene (DispersinBâ„¢), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using DispersinBâ„¢-based antimicrobial compositions.Type: ApplicationFiled: October 12, 2007Publication date: January 13, 2011Applicant: Kane Biotech Inc.Inventors: Srinivasa Madhyastha, Nanda Yakandawala, Purushottam V. Gawande, Karen Lovetri, Jeffrey B. Kaplan, Daniel Rhoads, Lasha Gogokhia
-
Publication number: 20110008418Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.Type: ApplicationFiled: August 3, 2010Publication date: January 13, 2011Inventor: Young Hee Ko
-
Publication number: 20110008361Abstract: A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.Type: ApplicationFiled: June 8, 2007Publication date: January 13, 2011Inventor: Judith Mary Bragger
-
Publication number: 20110002906Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.Type: ApplicationFiled: July 2, 2009Publication date: January 6, 2011Inventors: Harmeet Sidhu, Qingshan Li, Aaron Blake Cowley, Carl-Gustaf Golander
-
Publication number: 20100330061Abstract: Methods and devices useful for treatment of lung conditions resulting from dysfunction of normal pulmonary physiology.Type: ApplicationFiled: July 2, 2010Publication date: December 30, 2010Inventor: Gregory E. Conner
-
Publication number: 20100330013Abstract: Body care products, hair care products, shampoos, oral care, dental care and dental prosthesis care products, dental brace care products, cosmetics, therapeutics, washing agents, cleaning agents, brightening products, disinfectants, rinsing agents, hand washing products, dishwashing agents, machine dishwashing agents and agents for the bleaching and disinfecting treatment of filter media, textiles, furs, paper, skins or leather, and other products containing amadoriases are provided. Also, the use of amadoriases for decomposition products of the Amadori rearrangement is provided.Type: ApplicationFiled: November 7, 2008Publication date: December 30, 2010Applicant: HENKEL AG & CO. KGaAInventors: Timothy O'Connell, Nina Hoven, Petra Siegert, Karl-Heinz Maurer
-
Publication number: 20100330145Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.Type: ApplicationFiled: September 2, 2010Publication date: December 30, 2010Inventor: Stephen D. PACETTI
-
Publication number: 20100330191Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.Type: ApplicationFiled: August 24, 2010Publication date: December 30, 2010Inventors: Albert Missbichler, Franz Gabor, Herwig Reichl
-
Patent number: 7858084Abstract: The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can be activated by the body as needed. Active renalase protein can be administered to individuals needing an immediate reduction of catecholamine levels. An inhibitor of renalase may be used to enhance adrenergic action.Type: GrantFiled: November 21, 2006Date of Patent: December 28, 2010Assignee: Yale UniversityInventors: Gary Desir, Jianchao Xu
-
Publication number: 20100322872Abstract: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, lactoferrin, lactoferrin peptides, lysozyme and immunoglobulins and at least one growth factor.Type: ApplicationFiled: August 3, 2010Publication date: December 23, 2010Inventor: Jean-Paul Perraudin
-
Publication number: 20100316621Abstract: Provided is a prophylactic agent for an autoimmune disease, including a fraction of a milk-derived basic protein, lactoperoxidase, and lactoferrin as active ingredients. The agent can be taken on a daily basis, and even if it is taken over a long period of time, its safety is high, and hence, an autoimmune disease such as type I diabetes mellitus or rheumatoid arthritis, which could not be effectively prevented or treated by a conventional method, can be prevented.Type: ApplicationFiled: February 7, 2008Publication date: December 16, 2010Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventor: Hiroshi Kawakami